Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
October 28, 2022
RegMed Investors (RMi): Research Note: Solid Biosciences (SLDB) announces a 1-for-15 Reverse Stock Split
October 25, 2022
Syncona (SYNC) to acquire Applied Genetic Technologies Corporation (AGTC) update
October 20, 2022
Prime Medicine (PRME) a gene editing company has raised $175 million selling 1.4 million shares in the middle of its $17-$19 price range in its IPO
October 19, 2022
Avrobio (AVRO) received De-Listing Notice for being under $1.00 compliance with Nasdaq, has 180 days to correct
September 30, 2022
Solid Biosciences (SLDB) announces acquisition of Aavanti Bio Inc (private)and concurrent $75 Million Private Placement
September 28, 2022
RegMed Investors’ (RMi): What’s up Applied Genetic Technologies (AGTC)?
September 16, 2022
The Biostage (BSTG) Chronicles: Who is or what is behind the purchases and pump/promote of BSTG’s volume and share pricing?
August 30, 2022
RegMed Investors (RMI): burning investors, Applied Genetic Technologies (AGTC)
August 16, 2022
RegMed Investors’ (RMI) Earnings: dates of releases and more results
July 21, 2022
Verve Therapeutics (VERV) proposes $200 M offering priced at $27.00
July 13, 2022
Applied Genetic Technologies (AGTC) prices public offering of 16,66 M shares at $0.60
June 23, 2022
The Biostage (BSTG) Chronicles: filed an S-1 preliminary offering prospectus by Newbridge Securities Corporation.
June 2, 2022
Chinook Therapeutics (KDNY) public offering of 6,4 M shares priced at $14.00 raising $105 M
May 3, 2022
RegMed Investors: The week that will define the cell and gene therapy sector’s share pricing month
April 28, 2022
The Biostage (BSTG) Chronicles: Surgeon on trial in Sweden over experimental windpipe transplants
April 28, 2022
Alnylam Pharmaceuticals (ALNY) reports Q1/2022 earnings; net loss and net product revenue and collaboration decreases
March 22, 2022
Applied Genetic Technology (AGTC) prices 7.5 M share public offering
March 4, 2022
UC Berkeley loses CRISPR patent case, invalidating licenses it granted gene-editing companies
February 17, 2022
The Biostage (OTC: QB: BSTG) Chronicles: Who, What, When, Where, Why and one H (HOW)
January 11, 2022
The Biostage Chronicles: dispose and disregard, fit for the barrel
December 4, 2021
RegMed Investors (RMi): The week in review …
November 9, 2021
Chinook Therapeutics (KDNY) prices an upsized offering at $14.00 per share
October 30, 2021
The Biostage (BSTG) Chronicles: what’s there to invest in?
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors